Registry of Pancreatic Exocrine Insufficiency.
- Conditions
- Exocrine Pancreatic Insufficiency
- Interventions
- Drug: Pancreatic Enzyme
- Registration Number
- NCT05450627
- Lead Sponsor
- Hospital Clinico Universitario de Santiago
- Brief Summary
A prospective, cross-sectional, observational study has been designed with the aim of the study is to evaluate the diagnosis and management of patients with pancreatic exocrine insufficiency secondary to different pancreatic diseases and conditions in clinical practice.
A registry has been develop to include patients older than 18 years diagnosed with pancreatic exocrine insufficiency, sho are willing to participate in the study and sign the informed consent.
Registry includes demographics, toxic habits,pharmacological therapies, underlying disease that causes pancreatic exocrine insufficiency.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1000
- Patients older than 18 years diagnosed with PEI secondary to pancreatic diseases, pancreatectomy, or gastrectomy.
- Willingness to participate in the study.
- Patients with pancreatic diseases without PEI.
- Pregnancy
- Known allergy to oral pancreatic enzymes
- Any condition avoiding adequate clinical management of PEI.
- Patients who are not willing to participate in the study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Case Pancreatic Enzyme Adult patients diagnosed with pancreatic exocrine insufficiency of any etiology
- Primary Outcome Measures
Name Time Method Dose of oral pancreatic enzymes Six months Dose required for symptoms relief and normalization of the nutritional status
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hospital Clinico Universitario de Santiago
🇪🇸Santiago de Compostela, A Coruña, Spain